Clinical Data Touts Antidepressant Trial Data

Newton, MA-based Clinical Data (NASDAQ:[[ticker:CLDA]]), announced positive results from the second Phase III trial of its antidepressant, vilazodone. In a study of 481 patients, the drug reduced depression symptoms, was well tolerated, and did not seem to result in sexual side effects; the results were similar to those from the first Phase III trial, which were announced in March. Clinical Data says it intends to file for FDA approval of vilazodone by the end of 2009. Development of the drug has been supported in part through the $17 million sale of Clinical Data’s genomics division, Cogenics, to Beckman Coulter (NYSE:[[ticker:BEC]]), an Orange County, CA life sciences company.

Author: Roxanne Palmer

Roxanne Palmer is interning at Xconomy's Boston office this summer. She is currently pursuing a master's degree in science and medical Journalism at Boston University after graduating from Brown in 2008 with a degree in English. Her thesis was on Herman Melville's Civil War poetry. When not chronicling the ups and downs of Boston's tech industry, Roxanne enjoys drawing, swimming, and birdwatching. Follow her on Twitter at http://twitter.com/roxannedpalmer, or email her at [email protected]. View all posts by Roxanne Palmer